Astonea Labs Ltd Stock Price Today (NSE: ASTONEALAB)

Astonea Labs Ltd

ASTONEALABPharmaceuticals
273.75+0.00 (+0.00%)
Market Closed

Fundamental Score

...

Astonea Labs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Astonea Labs Ltd share price today is 273.75, up +0.00% on NSE/BSE as of 3 August 2026. Astonea Labs Ltd (ASTONEALAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 297.46 (Cr). The 52-week high for ASTONEALAB share price is 301.30 and the 52-week low is 118.00. At a P/E ratio of 65.81x, ASTONEALAB is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 11.97% and a debt-to-equity ratio of 0.75.

Astonea Labs Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
288.20
Low
254.65
Volume
2.2K
Change
+5.29%

Astonea Labs Ltd share price chart: 5.29% return over the past month. 52-week high ₹301.30, 52-week low ₹118.00.

Astonea Labs Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
273.75273.75273.75273.751.00K (Cr)
273.75273.75273.75273.750.00 (Cr)
273.75273.75273.75273.751.00K (Cr)
271.00271.00271.00271.000.00 (Cr)
264.75271.00264.75271.002.00K (Cr)
266.00266.05266.00266.052.00K (Cr)
261.75261.75261.75261.751.00K (Cr)
272.45272.45272.45272.451.00K (Cr)
278.00278.00278.00278.000.00 (Cr)
285.80285.80278.00278.002.00K (Cr)

Astonea Labs Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
273.75273.75273.75273.75+0.00%
260.00288.20256.00273.75+5.29%
232.00301.30230.55260.00+12.07%
160.00235.95130.05230.55+44.09%
150.00165.00150.00160.05+6.70%
158.50159.50145.00153.10-3.41%
152.50160.00151.50158.50+3.93%
154.00160.00150.00156.00+1.30%
150.20163.95137.00163.50+8.85%
150.00161.95118.00150.00+0.00%
164.90165.00138.05150.00-9.04%
173.55180.00161.00161.00-7.23%

AI Research Briefing

Powered by Gemini · 2026-08-01

Topline growth is exploding while net profit and cash conversion are collapsing under the weight of weak internal controls.

Research Confidence
4.5/10Low
MICRO-CAP DARK HORSEconsolidation — 1M return at 10.61%, 3M return at 82.58%expensive — P/E of 65.81x against industry P/E of 34.89x

WHAT'S HAPPENING NOW (last 2-4 weeks)

Astonea Labs filed its FY26 Annual Report on July 24, 2026, setting its 9th AGM for August 21, 2026, to vote on Memorandum of Association alterations and subsidiary investments up to ₹100 crore. Standalone FY26 figures show revenue up 51.3% to ₹147.58 crore, but net profit dropped 15.6% to ₹4.52 crore. Statutory auditors flagged internal financial controls over financial reporting as operating ineffectively as of March 31, 2026. Earlier in July, the company monetized non-core assets, selling a Gurugram property for ₹2.99 crore, and secured a Yemen SBDMA facility inspection certificate.

CORE STORY (THE REAL GAME)

Micro-cap speculative pharma expansion vehicle riding a high-multiple re-rating cycle on cosmetic and generic manufacturing, masking thin profitability and structural control flags.

Why Now
  • FY26 standalone revenue rose 51.3% to ₹147.58 crore but net profit fell 15.6% to ₹4.52 crore
  • Auditor flagged ineffective internal financial controls as of March 31, 2026
  • Upcoming AGM on August 21, 2026 seeks sweeping MOA alterations and subsidiary expansion authority
Potential Catalysts
  • Successful operational turnaround of Damaira Pharmaceuticals acquisition
  • Concrete revenue delivery from newly incorporated international subsidiaries
  • Remediation of internal control audit qualifications
Key Risks
  • Auditor-certified ineffective internal financial controls over financial reporting
  • Abyssal 5-year cumulative free cash flow of ₹-47.4 Cr
  • Extreme micro-cap liquidity trap risk with zero institutional backing (FII at 0.0%)
Institutional Activity

FII holdings dropped by 2.51% to flat 0.0%, leaving the micro-cap entirely at the mercy of retail and promoter blocks.

Macro Context

India pharma sector targets high-value complex generics and biopharma, but micro-cap compliance standards face severe regulatory scrutiny.

Order Book / Expansion

Acquired 25.74% stake in Damaira Pharmaceuticals for ₹6.25 crore; sold Gurugram property for ₹2.99 crore.

Cash Flow Quality

no — 5Y FCF is ₹-47.4 Cr, profits fail to materialize as cash

3–6 Month Outlook

Consolidation near resistance with elevated downside risk if micro-cap speculative liquidity evaporates.

Primary Thesis Risk

Auditor-flagged ineffective internal controls combined with negative free cash flow make this a high-probability capital trap.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

11.97%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

10.33%

Returns generated on total capital deployed

Good

Oper. Profit Margin (5Y Avg)

12.69%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Astonea Labs Ltd Valuation Check

Poor

Price to Earnings (P/E)

65.81x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

72.30%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.07%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Profit Growth (Quarterly YoY)

N/A

Net profit growth vs same quarter last year

Revenue Growth (Quarterly YoY)

N/A

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

0.75x

Total debt ÷ equity. Below 0.5 = financially healthy

Average

Interest Coverage Ratio

2.72x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-47.40 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Astonea Labs Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of ASTONEALAB across key market metrics for learning purposes.

Positive Indicators

2 factors identified

Balanced Promoter Holding (72.30%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

4 factors identified

Premium Valuation Risk (P/E: 65.81x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Negative Free Cash Flow (₹-47.40 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 0.07%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Astonea Labs Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Astonea Labs Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
16.8/100
274
₹297.46
65.8
Average
11.97%
Average
10.33%
Average
0.8
Good
0.00%
66.4/100
1991
₹468821.49
37.7
Average
15.95%
Good
20.53%
Excellent
0.1
Excellent
16.75%
Excellent
11.78%
Good
0.82%
56.3/100
8056
₹193163.97
73.6
Average
16.53%
Good
21.96%
Excellent
0.0
Excellent
5.71%
Good
8.67%
Good
0.41%
51.4/100
5123
₹169902.02
77.5
Average
27.43%
Excellent
15.19%
Good
1.8
Average
12.07%
Good
11.80%
Good
0.76%
Cipla Ltd...
CIPLA500087
40.2/100
1473
₹116131.81
30.5
Average
11.60%
Average
15.49%
Good
0.0
Excellent
9.94%
Good
8.01%
Good
0.90%
74.1/100
1078
₹115375.77
21.3
Average
21.25%
Excellent
21.14%
Excellent
0.5
Excellent
18.77%
Excellent
12.45%
Good
0.09%
Lupin Ltd...
LUPIN500257
83.4/100
2415
₹113976.53
20.0
Average
28.68%
Excellent
29.93%
Excellent
0.3
Excellent
37.02%
Excellent
13.02%
Good
0.72%
61.5/100
2470
₹105053.91
52.3
Average
13.12%
Average
13.50%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%
41/100
1148
₹102660.46
25.6
Average
11.22%
Average
13.04%
Average
0.2
Excellent
15.44%
Excellent
12.09%
Good
0.65%
24.6/100
1580
₹90035.87
25.4
Average
10.06%
Average
12.80%
Average
0.2
Excellent
0.80%
Average
6.32%
Good
0.26%
34.1/100
1816
₹84016.75
93.9
Average
18.30%
Good
17.76%
Good
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%

Astonea Labs Ltd Quarterly Performance

Latest quarterly metrics for ASTONEALAB — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

N/A

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

N/A

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Astonea Labs Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for ASTONEALAB — calculated from daily price history

47RSI 14
Neutral — RSI 47

Momentum is balanced — neither overbought nor oversold.

SMA 50
259
▲ Price above SMA 50 — Short-term bullish
SMA 200
185
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
2K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Astonea Labs Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Astonea Labs Ltd (ASTONEALAB) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Astonea Labs Ltd

About ASTONEALAB (Astonea Labs Ltd)

Astonea Labs Ltd is a dynamic pharmaceutical company dedicated to improving global health and well-being through the development, manufacturing, and distribution of high-quality ph...armaceutical and cosmetic products. Driven by innovation and a commitment to excellence, ASTONEALAB meticulously formulates and produces a diverse portfolio of medicines and personal care solutions designed to meet the evolving needs of patients and consumers worldwide. Our unwavering focus on research and development ensures that we remain at the forefront of scientific advancements, constantly exploring new therapeutic possibilities and pushing the boundaries of product efficacy and safety. ASTONEALAB strives to be a trusted partner for healthcare professionals and individuals seeking reliable and effective solutions for a healthier and more vibrant life. ASTONEALAB's product range encompasses a broad spectrum of therapeutic areas, addressing various health concerns and enhancing the quality of life. We offer a comprehensive selection of pharmaceutical products, including essential generic medications, over-the-counter remedies, specialized therapies targeting specific conditions, and innovative nutraceuticals designed to support overall wellness. Furthermore, ASTONEALAB's commitment to beauty and personal care is reflected in our extensive line of cosmetic products, which includes advanced skincare formulas, revitalizing haircare solutions, and age-defying treatments. Our dedication to quality extends across all product categories, ensuring that every item bearing the ASTONEALAB name meets the highest standards of purity, potency, and efficacy. ASTONEALAB operates with a global vision, extending its reach to serve diverse markets and communities around the world. We are committed to fostering strong partnerships with healthcare providers, distributors, and other stakeholders to ensure that our products are readily accessible to those who need them most. Through strategic collaborations and a robust distribution network, ASTONEALAB is expanding its presence in both established and emerging markets, bringing innovative healthcare solutions to a wider audience. We remain steadfast in our mission to make a positive impact on the health and well-being of individuals and communities worldwide, guided by our core values of integrity, innovation, and unwavering commitment to quality.

Company Details

Symbol:ASTONEALAB
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Ashish Gulati
MD & Director
Ms. Pooja Singh
Executive Director
Mr. Sumit Kumar
Chief Financial Officer

ASTONEALAB Share Price: Frequently Asked Questions

What is the current share price of Astonea Labs Ltd?

Astonea Labs Ltd (ASTONEALAB) trades at ₹273.75 on NSE and BSE. Market cap ₹297.46 (Cr). Educational data only.

What is the P/E ratio of Astonea Labs Ltd?

Astonea Labs Ltd has a P/E of 65.81x vs industry average 34.89x.

What is the Bull Run score for Astonea Labs Ltd?

Astonea Labs Ltd has a Bull Run score of 16.8/100 based on 25+ financial parameters.

Does Astonea Labs Ltd pay dividends?

Astonea Labs Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Astonea Labs Ltd?

Astonea Labs Ltd has ROE of 11.97%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Astonea Labs Ltd?

Astonea Labs Ltd has debt-to-equity of 0.75.

Is Astonea Labs Ltd a good investment?

Bull Run gives Astonea Labs Ltd a score of 16.8/100. This is not investment advice — consult a SEBI-registered advisor.